Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18"" wg kryterium: Temat


Tytuł :
HPV Vaccination and the Risk of Invasive Cervical Cancer.
Autorzy :
Lei J; From the Departments of Medical Epidemiology and Biostatistics (J.L., A.P., P.S.) and Laboratory Medicine (K.M.E., J.W., K.S., J.D.) and the Institute of Environmental Medicine (F.F.), Karolinska Institutet, the Regional Cancer Center Stockholm Gotland (K.M.E.), and the Karolinska University Laboratory, Karolinska University Hospital (J.D.), Stockholm, the Department of Communicable Disease Control and Health Protection, Public Health Agency of Sweden, Solna (A.R.), and the Department of Translational Medicine, Lund University, Lund (A.R.) - all in Sweden.
Ploner A; From the Departments of Medical Epidemiology and Biostatistics (J.L., A.P., P.S.) and Laboratory Medicine (K.M.E., J.W., K.S., J.D.) and the Institute of Environmental Medicine (F.F.), Karolinska Institutet, the Regional Cancer Center Stockholm Gotland (K.M.E.), and the Karolinska University Laboratory, Karolinska University Hospital (J.D.), Stockholm, the Department of Communicable Disease Control and Health Protection, Public Health Agency of Sweden, Solna (A.R.), and the Department of Translational Medicine, Lund University, Lund (A.R.) - all in Sweden.
Elfström KM; From the Departments of Medical Epidemiology and Biostatistics (J.L., A.P., P.S.) and Laboratory Medicine (K.M.E., J.W., K.S., J.D.) and the Institute of Environmental Medicine (F.F.), Karolinska Institutet, the Regional Cancer Center Stockholm Gotland (K.M.E.), and the Karolinska University Laboratory, Karolinska University Hospital (J.D.), Stockholm, the Department of Communicable Disease Control and Health Protection, Public Health Agency of Sweden, Solna (A.R.), and the Department of Translational Medicine, Lund University, Lund (A.R.) - all in Sweden.
Wang J; From the Departments of Medical Epidemiology and Biostatistics (J.L., A.P., P.S.) and Laboratory Medicine (K.M.E., J.W., K.S., J.D.) and the Institute of Environmental Medicine (F.F.), Karolinska Institutet, the Regional Cancer Center Stockholm Gotland (K.M.E.), and the Karolinska University Laboratory, Karolinska University Hospital (J.D.), Stockholm, the Department of Communicable Disease Control and Health Protection, Public Health Agency of Sweden, Solna (A.R.), and the Department of Translational Medicine, Lund University, Lund (A.R.) - all in Sweden.
Roth A; From the Departments of Medical Epidemiology and Biostatistics (J.L., A.P., P.S.) and Laboratory Medicine (K.M.E., J.W., K.S., J.D.) and the Institute of Environmental Medicine (F.F.), Karolinska Institutet, the Regional Cancer Center Stockholm Gotland (K.M.E.), and the Karolinska University Laboratory, Karolinska University Hospital (J.D.), Stockholm, the Department of Communicable Disease Control and Health Protection, Public Health Agency of Sweden, Solna (A.R.), and the Department of Translational Medicine, Lund University, Lund (A.R.) - all in Sweden.
Fang F; From the Departments of Medical Epidemiology and Biostatistics (J.L., A.P., P.S.) and Laboratory Medicine (K.M.E., J.W., K.S., J.D.) and the Institute of Environmental Medicine (F.F.), Karolinska Institutet, the Regional Cancer Center Stockholm Gotland (K.M.E.), and the Karolinska University Laboratory, Karolinska University Hospital (J.D.), Stockholm, the Department of Communicable Disease Control and Health Protection, Public Health Agency of Sweden, Solna (A.R.), and the Department of Translational Medicine, Lund University, Lund (A.R.) - all in Sweden.
Sundström K; From the Departments of Medical Epidemiology and Biostatistics (J.L., A.P., P.S.) and Laboratory Medicine (K.M.E., J.W., K.S., J.D.) and the Institute of Environmental Medicine (F.F.), Karolinska Institutet, the Regional Cancer Center Stockholm Gotland (K.M.E.), and the Karolinska University Laboratory, Karolinska University Hospital (J.D.), Stockholm, the Department of Communicable Disease Control and Health Protection, Public Health Agency of Sweden, Solna (A.R.), and the Department of Translational Medicine, Lund University, Lund (A.R.) - all in Sweden.
Dillner J; From the Departments of Medical Epidemiology and Biostatistics (J.L., A.P., P.S.) and Laboratory Medicine (K.M.E., J.W., K.S., J.D.) and the Institute of Environmental Medicine (F.F.), Karolinska Institutet, the Regional Cancer Center Stockholm Gotland (K.M.E.), and the Karolinska University Laboratory, Karolinska University Hospital (J.D.), Stockholm, the Department of Communicable Disease Control and Health Protection, Public Health Agency of Sweden, Solna (A.R.), and the Department of Translational Medicine, Lund University, Lund (A.R.) - all in Sweden.
Sparén P; From the Departments of Medical Epidemiology and Biostatistics (J.L., A.P., P.S.) and Laboratory Medicine (K.M.E., J.W., K.S., J.D.) and the Institute of Environmental Medicine (F.F.), Karolinska Institutet, the Regional Cancer Center Stockholm Gotland (K.M.E.), and the Karolinska University Laboratory, Karolinska University Hospital (J.D.), Stockholm, the Department of Communicable Disease Control and Health Protection, Public Health Agency of Sweden, Solna (A.R.), and the Department of Translational Medicine, Lund University, Lund (A.R.) - all in Sweden.
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Oct 01; Vol. 383 (14), pp. 1340-1348.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18*
Uterine Cervical Neoplasms/*prevention & control
Adolescent ; Adult ; Child ; Cohort Studies ; Female ; Follow-Up Studies ; Humans ; Immunization Programs ; Incidence ; Neoplasm Invasiveness ; Registries ; Sweden/epidemiology ; Uterine Cervical Neoplasms/epidemiology ; Uterine Cervical Neoplasms/pathology ; Vaccination ; Young Adult
Czasopismo naukowe
Tytuł :
Will HPV vaccination prevent cervical cancer?
Autorzy :
Rees CP; Centre for Global Public Health, Institute of Population Health Sciences, Barts and The London School of Medicine and Dentistry, Queen Mary University, London E1 2AB, UK.
Brhlikova P; Institute of Health and Society, Newcastle University, Newcastle NE2 4AX, UK.
Pollock AM; Institute of Health and Society, Newcastle University, Newcastle NE2 4AX, UK.
Pokaż więcej
Źródło :
Journal of the Royal Society of Medicine [J R Soc Med] 2020 Feb; Vol. 113 (2), pp. 64-78. Date of Electronic Publication: 2020 Jan 21.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18*
Papillomavirus Vaccines*
Papillomavirus Infections/*prevention & control
Uterine Cervical Neoplasms/*prevention & control
Uterine Cervical Neoplasms/*virology
Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic ; Female ; Humans ; Randomized Controlled Trials as Topic ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Cost-risk analysis of available cervix cancer vaccine: Situation analysis from Thailand.
Autorzy :
Wiwanitkit S; Wiwanitkit House, Bangkhae, Bangkok, Thailand.
Wiwanitkit V; Department of Biological Science, Joseph Ayo Babalola University, Ilesa, Osun, Nigeria.
Pokaż więcej
Źródło :
Journal of cancer research and therapeutics [J Cancer Res Ther] 2019 Oct-Dec; Vol. 15 (6), pp. 1421.
Typ publikacji :
Letter
MeSH Terms :
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*economics
Papillomavirus Vaccines/*economics
Uterine Cervical Neoplasms/*economics
Uterine Cervical Neoplasms/*prevention & control
Cost-Benefit Analysis ; Female ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/adverse effects ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/therapeutic use ; Humans ; Papillomavirus Vaccines/adverse effects ; Papillomavirus Vaccines/therapeutic use ; Thailand ; Uterine Cervical Neoplasms/immunology
Opinia redakcyjna
Tytuł :
Safety and Immunogenicity of the Quadrivalent HPV Vaccine in Japanese Boys: a Phase 3, Open-Label Study.
Autorzy :
Murata S; MSD K.K.
Takeuchi Y; Fukui General Hospital.
Yamanaka K; Shinjuku Higashiguchi Clinic.
Hayakawa J; Hayakawa Clinic.
Yoshida M; Ogikuboekimae Clinic.
Yokokawa R; MSD K.K.
Wakana A; MSD K.K.
Sawata M; MSD K.K.
Tanaka Y; MSD K.K.
Pokaż więcej
Źródło :
Japanese journal of infectious diseases [Jpn J Infect Dis] 2019 Sep 19; Vol. 72 (5), pp. 299-305. Date of Electronic Publication: 2019 May 31.
Typ publikacji :
Clinical Trial, Phase III; Journal Article
MeSH Terms :
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*adverse effects
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*immunology
Papillomavirus Infections/*prevention & control
Adolescent ; Antibodies, Viral/blood ; Asian Continental Ancestry Group ; Child ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Drug-Related Side Effects and Adverse Reactions/pathology ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/administration & dosage ; Humans ; Male ; Seroconversion
Czasopismo naukowe
Tytuł :
Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis.
Autorzy :
Jiang Y; School of Public Health (Shenzhen), Sun Yat-Sen University, Shenzhen, Guangdong, China.
Ni W; Department of Pharmaceutical and Health Economics, University of Southern California, Los Angeles, California, USA.
Wu J; School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China .
Pokaż więcej
Źródło :
BMJ open [BMJ Open] 2019 Nov 24; Vol. 9 (11), pp. e031186. Date of Electronic Publication: 2019 Nov 24.
Typ publikacji :
Journal Article
MeSH Terms :
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*therapeutic use
Papillomavirus Infections/*prevention & control
Papillomavirus Vaccines/*therapeutic use
Uterine Cervical Neoplasms/*prevention & control
China ; Cost-Benefit Analysis ; Female ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/economics ; Humans ; Models, Economic ; Papillomavirus Infections/economics ; Papillomavirus Infections/virology ; Papillomavirus Vaccines/economics ; Quality-Adjusted Life Years ; Uterine Cervical Neoplasms/economics ; Uterine Cervical Neoplasms/virology
Czasopismo naukowe
Tytuł :
The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia.
Autorzy :
Mahumud RA; Health Economics and Policy Research, Centre for Health, Informatics and Economic Research, University of Southern Queensland, Toowoomba, Queensland, Australia.; School of Commerce, University of Southern Queensland, Toowoomba, QLD Australia.; Health Economics Research, Health Systems and Population Studies Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.; Health and Epidemiology Research, Department of Statistics, University of Rajshahi, Rajshahi, Bangladesh.
Alam K; Health Economics and Policy Research, Centre for Health, Informatics and Economic Research, University of Southern Queensland, Toowoomba, Queensland, Australia.; School of Commerce, University of Southern Queensland, Toowoomba, QLD Australia.
Dunn J; Health Economics and Policy Research, Centre for Health, Informatics and Economic Research, University of Southern Queensland, Toowoomba, Queensland, Australia.; Cancer Research Centre, Cancer Council Queensland, Fortitude Valley, QLD, Australia.; Prostate Cancer Foundation of Australia, St Leonards NSW, Australia.
Gow J; Health Economics and Policy Research, Centre for Health, Informatics and Economic Research, University of Southern Queensland, Toowoomba, Queensland, Australia.; School of Commerce, University of Southern Queensland, Toowoomba, QLD Australia.; School of Accounting, Economics and Finance, University of KwaZulu-Natal, Durban, South Africa.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2019 Oct 09; Vol. 14 (10), pp. e0223658. Date of Electronic Publication: 2019 Oct 09 (Print Publication: 2019).
Typ publikacji :
Journal Article
MeSH Terms :
Cost-Benefit Analysis*
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*economics
Mass Vaccination/*economics
Papillomavirus Infections/*prevention & control
Uterine Cervical Neoplasms/*prevention & control
Australia ; Child ; Female ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/therapeutic use ; Humans ; Quality-Adjusted Life Years
Czasopismo naukowe
Tytuł :
Adverse events following Quadrivalent HPV vaccination reported in Sao Paulo State, Brazil, in the first three years after introducing the vaccine for routine immunization (March 2014 to December 2016).
Autorzy :
Mauro AB; Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Centro de Referência para Imunobiológicos Especiais, São Paulo, São Paulo, Brazil.
Fernandes EG; Secretaria de Estado da Saúde de São Paulo, Centro de Vigilância Epidemiológica Alexandre Vranjac, Divisão de Imunizações, São Paulo, São Paulo, Brazil.
Miyaji KT; Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Centro de Referência para Imunobiológicos Especiais, São Paulo, São Paulo, Brazil.
Arantes BA; Secretaria de Estado da Saúde de São Paulo, Centro de Vigilância Epidemiológica Alexandre Vranjac, Divisão de Imunizações, São Paulo, São Paulo, Brazil.
Valente MG; Secretaria de Estado da Saúde de São Paulo, Centro de Vigilância Epidemiológica Alexandre Vranjac, Divisão de Imunizações, São Paulo, São Paulo, Brazil.
Sato HK; Secretaria de Estado da Saúde de São Paulo, Centro de Vigilância Epidemiológica Alexandre Vranjac, Divisão de Imunizações, São Paulo, São Paulo, Brazil.
Sartori AMC; Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Centro de Referência para Imunobiológicos Especiais, São Paulo, São Paulo, Brazil.
Pokaż więcej
Źródło :
Revista do Instituto de Medicina Tropical de Sao Paulo [Rev Inst Med Trop Sao Paulo] 2019 Sep 12; Vol. 61, pp. e43. Date of Electronic Publication: 2019 Sep 12.
Typ publikacji :
Journal Article
MeSH Terms :
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*adverse effects
Adolescent ; Adult ; Adverse Drug Reaction Reporting Systems ; Brazil/epidemiology ; Child ; Female ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/administration & dosage ; Humans ; Immunization Schedule ; Papillomavirus Infections/prevention & control ; Population Surveillance ; Retrospective Studies ; Young Adult
Czasopismo naukowe
Tytuł :
Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up.
Autorzy :
Wei L; Department of Obstetrics and Gynecology, Peking University People's Hospital, 11 Xizhimen South Street, Beijing 100044, China.
Xie X; Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, 1 Xueshi Road, Hangzhou 310006, China.
Liu J; Department of Gynecologic Oncology, Cancer Center, Sun Yat-sen University, 651 Dongfeng Road East, Guangzhou 510060, China.
Zhao Y; Department of Obstetrics and Gynecology, Peking University People's Hospital, 11 Xizhimen South Street, Beijing 100044, China.
Chen W; Department of Cancer Epidemiology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 South Panjiayuan Lane, Beijing 100021, China.
Zhao C; Department of Obstetrics and Gynecology, Peking University People's Hospital, 11 Xizhimen South Street, Beijing 100044, China.
Wang S; Department of Cancer Epidemiology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 South Panjiayuan Lane, Beijing 100021, China.
Liao X; MSD R&D (China), 21 Rongda Road, Wangjing R&D Base, Zhongguancun Electronic Zone West Zone, Chaoyang District, Beijing 100012, China.
Shou Q; MSD R&D (China), 21 Rongda Road, Wangjing R&D Base, Zhongguancun Electronic Zone West Zone, Chaoyang District, Beijing 100012, China.
Qiu Y; MSD R&D (China), 21 Rongda Road, Wangjing R&D Base, Zhongguancun Electronic Zone West Zone, Chaoyang District, Beijing 100012, China.
Qiao Y; Department of Cancer Epidemiology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 South Panjiayuan Lane, Beijing 100021, China. Electronic address: .
Saah AJ; Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA. Electronic address: .
Pokaż więcej
Źródło :
Vaccine [Vaccine] 2019 Jun 12; Vol. 37 (27), pp. 3617-3624. Date of Electronic Publication: 2018 Aug 16.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*immunology
Papillomavirus Infections/*complications
Papillomavirus Infections/*prevention & control
Uterine Cervical Neoplasms/*prevention & control
Adult ; Asian Continental Ancestry Group ; China ; Double-Blind Method ; Female ; Follow-Up Studies ; Genitalia, Female/pathology ; Genitalia, Female/virology ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/administration & dosage ; Humans ; Immunization Schedule ; Middle Aged ; Placebos/administration & dosage ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study.
Autorzy :
Mikamo H; Aichi Medical University Hospital, Nagakute, Japan.
Yamagishi Y; Aichi Medical University Hospital, Nagakute, Japan.
Murata S; MSD K.K., Tokyo, Japan. Electronic address: .
Yokokawa R; MSD K.K., Tokyo, Japan.
Han SR; MSD K.K., Tokyo, Japan.
Wakana A; MSD K.K., Tokyo, Japan.
Sawata M; MSD K.K., Tokyo, Japan.
Tanaka Y; MSD K.K., Tokyo, Japan.
Pokaż więcej
Źródło :
Vaccine [Vaccine] 2019 Mar 14; Vol. 37 (12), pp. 1651-1658. Date of Electronic Publication: 2019 Feb 20.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunogenicity, Vaccine*
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*immunology
Papillomavirus Infections/*prevention & control
Adolescent ; Adult ; Homosexuality, Male ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/administration & dosage ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/adverse effects ; Humans ; Japan/epidemiology ; Male ; Papillomavirus Infections/epidemiology ; Papillomavirus Infections/transmission ; Patient Outcome Assessment ; Risk Factors ; Sex Factors ; Vaccination/methods ; Young Adult
Czasopismo naukowe
Tytuł :
Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative men.
Autorzy :
Pinto LA; HPV Immunology and HPV Serology Laboratories, Frederick National Laboratory for Cancer Research, Frederick, MD, United States. Electronic address: .
Wilkin TJ; Weill Cornell Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, NY, United States.
Kemp TJ; HPV Immunology and HPV Serology Laboratories, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
Abrahamsen M; Center for Immunization and Infection Research in Cancer, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.
Isaacs-Soriano K; Center for Immunization and Infection Research in Cancer, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.
Pan Y; HPV Immunology and HPV Serology Laboratories, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
Webster-Cyriaque J; University of North Carolina, Chapel Hill, NC, United States.
Palefsky JM; University of California, San Francisco, CA, United States.
Giuliano AR; Center for Immunization and Infection Research in Cancer, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.
Pokaż więcej
Źródło :
Vaccine [Vaccine] 2019 Apr 24; Vol. 37 (18), pp. 2502-2510. Date of Electronic Publication: 2019 Mar 30.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Observational Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Alphapapillomavirus/*immunology
Antibodies, Viral/*blood
HIV Infections/*complications
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*immunology
Mouth/*immunology
Papillomavirus Infections/*prevention & control
Adult ; Antibodies, Neutralizing/blood ; Antibody Affinity ; HIV Infections/epidemiology ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/administration & dosage ; Human papillomavirus 16/immunology ; Human papillomavirus 18/immunology ; Humans ; Kinetics ; Male ; Middle Aged ; Papillomavirus Infections/immunology ; Vaccination ; Young Adult
Czasopismo naukowe
Tytuł :
Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine.
Autorzy :
Godi A; Virus Reference Department, Public Health England, London, UK.
Panwar K; Virus Reference Department, Public Health England, London, UK.
Haque M; Virus Reference Department, Public Health England, London, UK.
Cocuzza CE; Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Andrews N; Statistics, Modelling and Economics Department, Public Health England, London, UK.
Southern J; Immunisation and Countermeasures Public Health England, London, UK.
Turner P; Section of Paediatrics, Imperial College London, London, UK.
Miller E; Immunisation and Countermeasures Public Health England, London, UK.
Beddows S; Virus Reference Department, Public Health England, London, UK. Electronic address: .
Pokaż więcej
Źródło :
Vaccine [Vaccine] 2019 Apr 24; Vol. 37 (18), pp. 2455-2462. Date of Electronic Publication: 2019 Mar 27.
Typ publikacji :
Clinical Trial, Phase IV; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Neutralizing/*immunology
Antibodies, Viral/*immunology
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*immunology
Papillomavirus Infections/*prevention & control
Papillomavirus Vaccines/*immunology
Adolescent ; Antibodies, Neutralizing/blood ; Antibodies, Viral/blood ; Cross Protection ; Female ; Genotype ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/administration & dosage ; Humans ; Papillomaviridae/classification ; Papillomaviridae/immunology ; Papillomavirus Infections/immunology ; Papillomavirus Vaccines/administration & dosage ; Time Factors
Czasopismo naukowe
Tytuł :
Changes in Cervical Human Papillomavirus (HPV) Prevalence at a Youth Clinic in Stockholm, Sweden, a Decade After the Introduction of the HPV Vaccine.
Autorzy :
Ährlund-Richter A; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
Cheng L; Department of Microbiology, Tumor and Cell Biology, Centre for Translational Microbiome Research, Karolinska Institutet, Stockholm, Sweden.
Hu YOO; Department of Microbiology, Tumor and Cell Biology, Centre for Translational Microbiome Research, Karolinska Institutet, Stockholm, Sweden.; Science for Life Laboratory, Department of Microbiology, Tumor and Cell Biology, Stockholm, Sweden.
Svensson M; Department of Microbiology, Tumor and Cell Biology, Centre for Translational Microbiome Research, Karolinska Institutet, Stockholm, Sweden.
Pennhag AAL; Department of Microbiology, Tumor and Cell Biology, Centre for Translational Microbiome Research, Karolinska Institutet, Stockholm, Sweden.; Science for Life Laboratory, Department of Microbiology, Tumor and Cell Biology, Stockholm, Sweden.
Ursu RG; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.; Department of Microbiology (Bacteriology, Virology) and Parasitology, Grigore T. Popa University of Medicine and Pharmacy, Iaşi, Romania.
Haeggblom L; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
Grün N; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
Ramqvist T; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
Engstrand L; Department of Microbiology, Tumor and Cell Biology, Centre for Translational Microbiome Research, Karolinska Institutet, Stockholm, Sweden.; Science for Life Laboratory, Department of Microbiology, Tumor and Cell Biology, Stockholm, Sweden.
Dalianis T; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
Du J; Department of Microbiology, Tumor and Cell Biology, Centre for Translational Microbiome Research, Karolinska Institutet, Stockholm, Sweden.
Pokaż więcej
Źródło :
Frontiers in cellular and infection microbiology [Front Cell Infect Microbiol] 2019 Mar 20; Vol. 9, pp. 59. Date of Electronic Publication: 2019 Mar 20 (Print Publication: 2019).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Cervix Uteri/*virology
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*immunology
Papillomaviridae/*isolation & purification
Papillomavirus Infections/*epidemiology
Papillomavirus Infections/*prevention & control
Adult ; Female ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/administration & dosage ; Humans ; Molecular Epidemiology ; Papillomaviridae/classification ; Papillomaviridae/genetics ; Papillomavirus Infections/virology ; Prevalence ; Sweden/epidemiology ; Young Adult
Czasopismo naukowe
Tytuł :
Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up.
Autorzy :
Chen W; Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 South Panjiayuan Lane, Beijing, 100021, China. Electronic address: .
Zhao Y; Department of Obstetrics and Gynecology, Peking University People's Hospital, 11 Xizhimen South Street, Beijing 100044, China.
Xie X; Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, 1 Xueshi Road, Hangzhou 310006, China. Electronic address: .
Liu J; Department of Gynecologic Oncology, Cancer Center, Sun Yat-sen University, 651 Dongfeng Road East, Guangzhou 510060, China. Electronic address: .
Li J; Department of Obstetrics and Gynecology, Peking University People's Hospital, 11 Xizhimen South Street, Beijing 100044, China.
Zhao C; Department of Obstetrics and Gynecology, Peking University People's Hospital, 11 Xizhimen South Street, Beijing 100044, China.
Wang S; Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 South Panjiayuan Lane, Beijing, 100021, China. Electronic address: .
Liao X; MSD R&D (China), 21 Rongda Road, Wangjing R&D Base, Zhongguancun Electronic Zone West Zone, Chaoyang District, Beijing 100012, China. Electronic address: .
Shou Q; MSD R&D (China), 21 Rongda Road, Wangjing R&D Base, Zhongguancun Electronic Zone West Zone, Chaoyang District, Beijing 100012, China. Electronic address: .
Zheng M; MSD R&D (China), 21 Rongda Road, Wangjing R&D Base, Zhongguancun Electronic Zone West Zone, Chaoyang District, Beijing 100012, China. Electronic address: .
Saah AJ; Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA. Electronic address: .
Wei L; Department of Obstetrics and Gynecology, Peking University People's Hospital, 11 Xizhimen South Street, Beijing 100044, China. Electronic address: .
Qiao Y; Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 South Panjiayuan Lane, Beijing, 100021, China. Electronic address: .
Pokaż więcej
Źródło :
Vaccine [Vaccine] 2019 Feb 04; Vol. 37 (6), pp. 889-897. Date of Electronic Publication: 2019 Jan 09.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Viral/*blood
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*administration & dosage
Papillomavirus Infections/*prevention & control
Adult ; Asian Continental Ancestry Group ; China ; Double-Blind Method ; Female ; Follow-Up Studies ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/immunology ; Humans ; Middle Aged ; Vaccination/adverse effects ; Vaccination/statistics & numerical data ; Vaccine Potency ; Young Adult
Czasopismo naukowe
Tytuł :
Long-term Antibody Response to Human Papillomavirus Vaccines: Up to 12 Years of Follow-up in the Finnish Maternity Cohort.
Autorzy :
Artemchuk H; Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Eriksson T; University of Tampere, Finland.
Poljak M; Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Slovenia.
Surcel HM; Faculty of Medicine, University of Oulu, Oulu, Finland.; European Science Infrastructure Services, Oulu, Finland.
Dillner J; Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.; Clinical Pathology/Cytology, Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden.
Lehtinen M; Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.; University of Tampere, Finland.
Faust H; Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Pokaż więcej
Źródło :
The Journal of infectious diseases [J Infect Dis] 2019 Jan 29; Vol. 219 (4), pp. 582-589.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibody Formation*
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*immunology
Papillomaviridae/*immunology
Papillomavirus Vaccines/*immunology
Adolescent ; Antibodies, Viral/blood ; Female ; Finland ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/administration & dosage ; Humans ; Immunoassay ; Longitudinal Studies ; Papillomavirus Vaccines/administration & dosage
Czasopismo naukowe
Tytuł :
Persistence of Immunity When Using Different Human Papillomavirus Vaccination Schedules and Booster-Dose Effects 5 Years After Primary Vaccination.
Autorzy :
Lazcano-Ponce E; Center for Population Health Research, National Institute of Public Health, Morelos, Mexico.
Torres-Ibarra L; Center for Population Health Research, National Institute of Public Health, Morelos, Mexico.
Cruz-Valdez A; Center for Population Health Research, National Institute of Public Health, Morelos, Mexico.
Salmerón J; Center for Population Health Research, National Institute of Public Health, Morelos, Mexico.; Research Center on Policies, Population, and Health, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
Barrientos-Gutiérrez T; Center for Population Health Research, National Institute of Public Health, Morelos, Mexico.
Prado-Galbarro J; Center for Population Health Research, National Institute of Public Health, Morelos, Mexico.
Stanley M; Department of Pathology, University of Cambridge, United Kingdom.
Muñoz N; National Cancer Institute of Colombia, Bogotá.
Herrero R; Early Detection and Prevention Section, International Agency for Research on Cancer, Lyon, France.
Hernández-Ávila M; Center for Population Health Research, National Institute of Public Health, Morelos, Mexico.
Pokaż więcej
Źródło :
The Journal of infectious diseases [J Infect Dis] 2019 Jan 01; Vol. 219 (1), pp. 41-49.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunization, Secondary*
Vaccination*
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*immunology
Papillomavirus Infections/*prevention & control
Papillomavirus Vaccines/*immunology
Adolescent ; Antibodies, Viral/blood ; Child ; Dose-Response Relationship, Drug ; Enzyme-Linked Immunosorbent Assay ; Female ; Follow-Up Studies ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/administration & dosage ; Human papillomavirus 16/immunology ; Human papillomavirus 18/immunology ; Humans ; Immunization Schedule ; Non-Randomized Controlled Trials as Topic ; Papillomavirus Infections/blood ; Papillomavirus Infections/immunology ; Papillomavirus Vaccines/administration & dosage ; Papillomavirus Vaccines/blood ; Young Adult
Czasopismo naukowe
Tytuł :
Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later - an exploratory study.
Autorzy :
Gilca V; a Direction des risques biologiques et de la santé au travail , Quebec Public Health Institute , Quebec , Canada.; b Laval University Research Hospital Center , Quebec , Canada.
Sauvageau C; a Direction des risques biologiques et de la santé au travail , Quebec Public Health Institute , Quebec , Canada.; b Laval University Research Hospital Center , Quebec , Canada.
Panicker G; c Division of High-Consequence Pathogens and pathology , Centers for Disease Control and Prevention , Atlanta , GA , USA.
De Serres G; a Direction des risques biologiques et de la santé au travail , Quebec Public Health Institute , Quebec , Canada.; b Laval University Research Hospital Center , Quebec , Canada.
Ouakki M; a Direction des risques biologiques et de la santé au travail , Quebec Public Health Institute , Quebec , Canada.
Unger ER; c Division of High-Consequence Pathogens and pathology , Centers for Disease Control and Prevention , Atlanta , GA , USA.
Pokaż więcej
Źródło :
Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2019; Vol. 15 (2), pp. 503-507. Date of Electronic Publication: 2018 Sep 27.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Administration Schedule*
Antibodies, Viral/*blood
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*immunology
Papillomavirus Vaccines/*immunology
Adolescent ; Female ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/administration & dosage ; Humans ; Immunization Schedule ; Papillomavirus Infections/prevention & control ; Papillomavirus Vaccines/administration & dosage ; Qualitative Research ; Time Factors
Czasopismo naukowe
Tytuł :
Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1.
Autorzy :
Cespedes MS; Division of Infectious Disease, Icahn School of Medicine at Mount Sinai, New York, NY, United States. Electronic address: .
Kang M; Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA, United States.
Kojic EM; Division of Infectious Disease, Brown University, Providence, RI, United States.
Umbleja T; Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA, United States.
Godfrey C; HIV Research Branch, TRP, DAIDS, NIAID, NIH, Bethesda, MD, United States.
Webster-Cyriaque JY; Departments of Microbiology, Immunology, and Dental Ecology, University of North Carolina, Chapel Hill, NC, United States.
Masih R; ACTG Network Coordinating Center, Social & Scientific Systems, Silver Spring, MD, United States.
Firnhaber C; Clinical HIV Research Unit, Department of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, South Africa.
Grinsztejn B; Infectious Diseases Department, Instituto de Pesquisa Clinica Evandro Chagas Fiocruz, Rio de Janeiro, Brazil.
Saah A; Merck & Co., Inc., Kenilworth, NJ, United States.
Cu-Uvin S; Division of Infectious Disease, Brown University, Providence, RI, United States.
Aberg JA; Division of Infectious Disease, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Pokaż więcej
Źródło :
Papillomavirus research (Amsterdam, Netherlands) [Papillomavirus Res] 2018 Dec; Vol. 6, pp. 15-21. Date of Electronic Publication: 2018 Aug 16.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Anal Canal/*virology
Cervix Uteri/*virology
DNA, Viral/*analysis
HIV Infections/*complications
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*immunology
Papillomavirus Infections/*immunology
Papillomavirus Infections/*prevention & control
Adolescent ; Adult ; Antibodies, Neutralizing/blood ; Antibodies, Viral/blood ; DNA, Viral/genetics ; Female ; HIV Infections/immunology ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/administration & dosage ; Humans ; Immunologic Memory ; Papillomavirus Infections/epidemiology ; Prevalence ; Prospective Studies ; Young Adult
Czasopismo naukowe
Tytuł :
Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status.
Autorzy :
Mugo NR; Kenya Medical Research Institute, Center for Clinical Research, Kenya; Department of Global Health, University of Washington, Seattle, WA, USA; Partners in Health Research and Development, Kenya. Electronic address: .
Eckert L; Department of Obstetrics and Gynaecology, University of Washington, WA, USA.
Magaret AS; Department of Laboratory Medicine, University of Washington, Seattle, WA, USA; Department of Biostatistics, University of Washington, Seattle, WA, USA; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Cheng A; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Mwaniki L; Partners in Health Research and Development, Kenya.
Ngure K; Department of Global Health, University of Washington, Seattle, WA, USA; Jomo Kenyatta University of Agriculture and Technology, Kenya.
Celum C; Department of Global Health, University of Washington, Seattle, WA, USA; Departments of Medicine, University of Washington, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA.
Baeten JM; Department of Global Health, University of Washington, Seattle, WA, USA; Departments of Medicine, University of Washington, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA.
Galloway DA; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Wamalwa D; University of Nairobi, Kenya.
Wald A; Department of Laboratory Medicine, University of Washington, Seattle, WA, USA; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Departments of Medicine, University of Washington, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA.
Pokaż więcej
Źródło :
Vaccine [Vaccine] 2018 Nov 12; Vol. 36 (46), pp. 7025-7032. Date of Electronic Publication: 2018 Oct 05.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunogenicity, Vaccine*
Drug-Related Side Effects and Adverse Reactions/*epidemiology
HIV Infections/*complications
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*adverse effects
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*immunology
Papillomavirus Infections/*prevention & control
Adolescent ; Antibodies, Viral/blood ; Child ; Drug-Related Side Effects and Adverse Reactions/pathology ; Female ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/administration & dosage ; Humans ; Immunization Schedule ; Kenya ; Male ; United States
Czasopismo naukowe
Tytuł :
Serum and cervicovaginal IgG immune responses against α7 and α9 HPV in non-vaccinated women at risk for cervical cancer: Implication for catch-up prophylactic HPV vaccination.
Autorzy :
Mboumba Bouassa RS; Laboratoire de virologie, hôpital européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.; Ecole Doctorale Régionale en Infectiologie Tropicale, Franceville, Gabon.; Université Paris Descartes, Paris Sorbonne Cité, Paris, France.; INSERM UMR_S970, Immunothérapie et traitement anti-angiogénique en cancérologie, Paris Centre de Recherche Cardiovasculaire (PARCC), hôpital européen Georges Pompidou, AP-HP, Paris, France.
Péré H; Laboratoire de virologie, hôpital européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.; Université Paris Descartes, Paris Sorbonne Cité, Paris, France.; INSERM UMR_S970, Immunothérapie et traitement anti-angiogénique en cancérologie, Paris Centre de Recherche Cardiovasculaire (PARCC), hôpital européen Georges Pompidou, AP-HP, Paris, France.
Gubavu C; Service des maladies infectieuses et tropicales, Centre hospitalier régional d'Orléans and Centre Gratuit d'Information, de Dépistage et de Diagnostic (CEGIDD) d'Orléans, Orléans, France.
Prazuck T; Service des maladies infectieuses et tropicales, Centre hospitalier régional d'Orléans and Centre Gratuit d'Information, de Dépistage et de Diagnostic (CEGIDD) d'Orléans, Orléans, France.
Jenabian MA; Département des Sciences Biologiques et Centre de Recherche BioMed, Université du Québec à Montréal (UQAM), Montreal, Quebec, Canada.
Veyer D; Laboratoire de virologie, hôpital européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Meye JF; Service de Gynécologie Obstétrique, Centre Hospitalo-Universitaire d'Agondjé et Faculté de Médecine de Libreville, Université des Sciences de la Santé, Libreville, Gabon.
Touzé A; UMRINRA ISP 1282, Equipe Biologie des infections à polyomavirus, Université de Tours, Tours, France.
Bélec L; Laboratoire de virologie, hôpital européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.; Ecole Doctorale Régionale en Infectiologie Tropicale, Franceville, Gabon.; Université Paris Descartes, Paris Sorbonne Cité, Paris, France.; INSERM UMR_S970, Immunothérapie et traitement anti-angiogénique en cancérologie, Paris Centre de Recherche Cardiovasculaire (PARCC), hôpital européen Georges Pompidou, AP-HP, Paris, France.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 May 18; Vol. 15 (5), pp. e0233084. Date of Electronic Publication: 2020 May 18 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Viral/*metabolism
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/*immunology
Papillomavirus Infections/*diagnosis
Uterine Cervical Neoplasms/*virology
Adult ; Africa South of the Sahara/ethnology ; Antibodies, Viral/blood ; Cervix Uteri/immunology ; Early Detection of Cancer ; Emigrants and Immigrants/statistics & numerical data ; Female ; France/ethnology ; Human papillomavirus 16/immunology ; Human papillomavirus 18/immunology ; Humans ; Middle Aged ; Papillomavirus Infections/immunology ; Uterine Cervical Neoplasms/immunology ; Vagina/immunology
Czasopismo naukowe
Tytuł :
Sponsorship bias in clinical trials: growing menace or dawning realisation?
Autorzy :
Jefferson T; Senior Associate Tutor, University of Oxford; Researcher, Nordic Cochrane Centre; Visiting Professor, Newcastle University, UK.
Pokaż więcej
Źródło :
Journal of the Royal Society of Medicine [J R Soc Med] 2020 Apr; Vol. 113 (4), pp. 148-157.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Bias*
Drug Industry*
Research Design*
Clinical Trials as Topic/*economics
Antiviral Agents ; Drug Approval ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Oseltamivir
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies